The approval gives Boehringer and Lilly an opportunity to regain ascendency in the SGLT2 market after a prolonged period of sustained growth for AZ's Forxiga (dapagliflozin) – known as Farxiga ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback